Atrial Fibrillation

Atrial Fibrillation (A-Fib) afflicts over 2.2 million people in the United States and, according to the American Heart Association (AHA), led to over 470,000 hospitalizations in 2003. A-Fib can be acute or chronic and is a condition characterized by chaotic electrical activity in the upper chambers of the heart, also known as the atria. It can cause shortness of breath, chest pain, or dizziness and can also cause blood clots, often leading to a stroke.

Current therapies for A-Fib are limited by side effects and poor efficacy and there remains a significant need for drugs that can control heart rhythm without the side effects of current therapies.

K201 (JTV-519)

Sequel is developing K201 (JTV-519) for the treatment of A-Fib. K201, which has a unique, multi-ion channel profile, has the potential to treat A-Fib without the side effects associated with current therapies.